MR imaging detection of cerebral metastases with a single injection of high-dose gadoteridol

J Magn Reson Imaging. 1994 Sep-Oct;4(5):669-73. doi: 10.1002/jmri.1880040509.


The utility of a single high-dose (0.3 mmol/kg) injection of gadoteridol, a gadolinium chelate, in the detection of brain metastases on magnetic resonance images was studied. Patients (n = 29) with a high suspicion for brain metastases at clinical examination and by history were imaged on two occasions--separated by more than 24 hours and less than 7 days--with a 0.1 mmol/kg contrast agent dose used for the first study and a 0.3 mmol/kg dose for the second. In patients (n = 15) with confirmed brain metastases by clinical, radiologic, and/or histologic criteria, 40 lesions were detected at the 0.3 mmol/kg dose by a single reader blinded to contrast agent dose, compared with 33 lesions at 0.1 mmol/kg, a 21% increase. Three of 15 patients (20%) demonstrated an increase in the number of lesions detected at the higher dose. Region-of-interest analysis of signal intensity measurements showed that lesion contrast (relative to normal brain) improved from 54% at 0.1 mmol/kg to 92% at 0.3 mmol/kg. A 0.3 mmol/kg dose of gadoteridol, administered in a single injection, permits identification of brain metastases not detected at 0.1 mmol/kg. Such information can influence the choice of therapy.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Brain Neoplasms / diagnosis*
  • Brain Neoplasms / secondary*
  • Contrast Media* / administration & dosage
  • Gadolinium* / administration & dosage
  • Heterocyclic Compounds* / administration & dosage
  • Humans
  • Image Enhancement* / methods
  • Magnetic Resonance Imaging* / methods
  • Middle Aged
  • Organometallic Compounds* / administration & dosage
  • Prospective Studies
  • Sensitivity and Specificity
  • Single-Blind Method


  • Contrast Media
  • Heterocyclic Compounds
  • Organometallic Compounds
  • gadoteridol
  • Gadolinium